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We have investigated early programming of body mass in order to understand the
multifactorial etiology of obesity. Considering that the renin-angiotensin system (RAS)
is expressed and functional in the white adipose tissue (WAT) and modulates its
development, we reasoned whether early transitory inhibition of angiotensin-I converting
enzyme activity after birth couldmodify late bodymass development. Therefore, newborn
Wistar rats were treated with enalapril (10mg/kg of body mass) or saline, starting at
the first day of life until the age of 16 days. Between days ninetieth and hundred and
eightieth, a group of these animals received high fat diet (HFD). Molecular, biochemical,
histological, and physiological data were collected. Enalapril treated animals presented
hyperphagia, overweight, and increased serum level of triglycerides, total cholesterol
and leptin, in adult life. Body composition analyses revealed higher fat mass with
increased adipocyte size in these animals. Molecular analyses revealed that enalapril
treatment increases neuropeptide Y (NPY) and cocaine- and amphetamine-regulated
transcript (CART) gene expression in hypothalamus, fatty acid synthase (FAS), and
hormone-sensitive lipase (HSL) gene expression in retroperitoneal WAT, and decreases
peroxixome proliferators-activated receptor (PPAR)γ, PPARα, uncoupling protein (UCP)2,
and UCP3 gene expression in WAT. The results of the current study indicate that enalapril
administration during early postnatal development increases body mass, adiposity
and serum lipids in adulthood associated with enhanced food intake and decreased
metabolic activity in WAT, predisposing to obesity in adulthood.
Keywords: renin-angiotensin system, overweight, hyperphagia, NPY, PPAR, UCP
Introduction
Epidemiological studies have revealed associations between critical events in the early phases of
development, such as pregnancy and suckling, and metabolic, cardiovascular diseases in the adult
life (Langley-Evans, 2006, 2015). The adipose tissue is among the tissues that undergo modification
in the postnatal life and its characteristics become essential to the development of obesity.
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White adipose tissue (WAT) is composed of different cellular
types such as preadipocytes, mature adipocytes, and pluripotent
mesenchymal cells of the connective tissue, whose features can
be determined by specific events in critical phases of their devel-
opment (Mostyn and Symonds, 2009). Early nutritional alter-
ations have high impact on the metabolism in adulthood, in
human and animals. Children with malnutrition events present
deficiency in the mechanism of fat oxidation and therefore have
higher risk to develop obesity (Hoffman et al., 2000). Restric-
tion of protein during pregnancy and lactation increases visceral
adiposity in the adult and modifies the expression of genes that
control the metabolism, as the expression of fatty acid synthase
(FAS) enzyme in the visceral WAT, and other genes involved
with adipocyte differentiation, angiogenesis and remodeling of
extracellular matrix (Guan et al., 2005). Gorski et al. (2006)
demonstrated that postnatal factors can overcome both genetic
predisposition and prenatal factors in determining the develop-
ment of adiposity, insulin sensitivity, and the brain pathways that
mediate these functions. These authors have shown that obesity-
prone pup cross-fostered to obesity-resistant dams remained
obese but improved their insulin sensitivity in adult life (Gorski
et al., 2006). In contrast, obesity-resistant pups cross-fostered
to genetically obese dams showed a diet-induced increase in
adiposity, reduced insulin sensitivity and associated changes in
hypothalamic neuropeptide, insulin, and leptin receptors, which
might have contributed to their metabolic defects (Gorski et al.,
2006).
The WAT is known to produce and secrete key substances
for energy metabolism control and other functions. Among these
substances are the components of the renin-angiotensin system
(RAS), which have been initially described only as involved in
the control of arterial pressure (Cassis et al., 1988). The WAT
also secretes tumor necrosis factor (TNF) α and interleukins,
important hormones for signaling in the immune system and
inflammatory response, respectively. In addition to the systemic
effect of angiotensin II (AngII) in the regulation of blood pres-
sure, several other functions of AngII produced by the adipocyte
have been suggested: AngII has been associated with the progres-
sion of the cellular cycle of human preadipocytes (Crandall et al.,
1999); AngII stimulates the production and release of prostacy-
clins from the adipocytes, which in turn, stimulates adipogenesis
of adipose precursory cells (Saint-Marc et al., 2001); and AngII
increases lipogenesis and triglycerides accumulation in 3T3-L1
cells and adipocytes (Jones et al., 1997). In accordance with these
metabolic effects produced by AngII, it is also observed that rats
treated with antagonist of the AngII receptor (losartan) show
reduction in adipocyte size (Zorad et al., 1995). Moreover, results
fromMassiera et al. (2001) using angiotensinogen knockout mice
submitted to high fat diet (HFD) show that AngII has local func-
tion in the development of the WAT and its cellularity. These
mice have lower percentage of body fat mass, higher number of
adipocytes and reduced diameter and cellular weight, reduction
of the activity of the enzyme fat acid synthase and similar levels of
lean mass, locomotor activity and metabolic rate when compared
to the lean controls. Deficiency of other genes of the RAS, as AT1
and AT2 receptors, independently, generates animals resistant to
HFD induced obesity and insulin intolerance (Kouyama et al.,
2005; Yvan-Charvet et al., 2005). Yvan-Charvet et al. (2005) have
shown that AT2 receptor knockout mice present normal adipos-
ity compared with the controls, but higher number of adipocytes
with reduced size. In these animals, lipid oxidation was increased,
as well as the expression of genes involved in the metabolism of
the lipids in the muscle as UCP3, PPARα, PPARγ, and fatty acid
translocase.
Early reports have shown that angiotensin converting enzyme
(ACE) inhibitors treatment is effective in decreasing body weight
in animals and humans, however its mechanism of action has
not been elucidated (Masuo et al., 2001; Santos et al., 2008).
In agreement, Lemes et al. (2013), recently showed that the
ACE DD genotype is correlated with higher serum ACE lev-
els and is associated with arterial hypertension and with obe-
sity related traits in boys, but not in girls, in a cohort of obese
children and adolescents. In contrast, Heimann et al. (2005),
have used mice harboring 1, 2, or 3 copies of the ACE gene
to evaluate the quantitative role of the ACE locus on obe-
sity. They have shown that three-copy mice fed with a high-fat
diet had lower body weight and peri-epididymal adipose tissue
when compared to mice harboring one- and two-ACE copies.
Despite this body of knowledge linking the RAS with the adi-
pose tissue and metabolism, the controversy remains regarding
the real role of ACE activity in energy metabolism and obe-
sity. In addition, little is known about the effects of the mod-
ulation of this system on the postnatal life. Thus, based on the
rationale that environmental factors could have influence on
ACE activity, especially in critical phases of the development,
resulting in different phenotypic possibilities (Levy-Marchal and
Czernichow, 2006), we investigated the impact of early inhi-
bition of ACE activity on body mass development in adult
life.
Material and Methods
Animals and Experimental Procedures
All aspects of animal care and experimentation performed in this
study agreed with ethical principles in animal research adopted
by the Brazil’s National Council of Animal Experimentation
(CONCEA) and were approved by the Ethical Committee for
Animal Research (Protocol 1015/06) from the Federal University
of São Paulo. The male rats were separated after pregnancy con-
firmation and the female rats were maintained during pregnancy
period in a temperature-controlled room (23± 1◦C) with a 12-h
light-dark cycle (lights on at 07:00 h), with free access to food and
water.
As presented in the experimental schedule below (Figure 1),
after birth, eight male offsprings by dam received daily either
ACE inhibitor (enalapril, 10mg/kg of BW) or saline for 16 days.
Between the twenty first (weaning) and ninetieth day of life the
rats were kept in standard conditions, five animals by cage, with-
out any experimental manipulation. The rats were randomly
assigned at the ninetieth day into two groups (10 animals each
group). Each group received either control diet (17 kJ/g–10 kcal%
fat, Research Diets, Inc.–CD) or HFD (21 kJ/g–45 kcal% fat,
Research Diets, Inc.–HFD) for 3 months. For assessment of water
intake and urine excretion, the rats (180-day-old) were main-
tained in metabolic cages for 48 h (Figure 1). After this time, the
rats were sacrificed by decapitation and the blood was collected
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FIGURE 1 | Schematic representation of the treatments performed in the different group of animals from birth to the age of 180 days.
and centrifuged at 1000 g for 20min. Samples of WAT (epi-
didymal, retroperitoneal and mesenteric—gastrointestinal; and
inguinal—subcutaneous) and hypothalamus were weighted and
quickly frozen. Kidney, liver, and heart were weighted to evaluate
relative mass (g of organ/100 g of body mass).
Body Composition
At the hundred and eightieth day of life the rats were anesthetized
with ketamine plus xylazine (1:1, 0,1ml/kg) and submitted to
body composition analysis. The indirect body composition was
analyzed by dual-energy X-ray absorptiometry (DEXA), using a
hologic QDR 2000 system (software v 5.54). Lean mass and fat
mass (% of total mass) were determined using the whole body
(excluding head and tail).
Serum Measurements
The 180-day-old animals were sacrificed between 8:00 and 12:00
a.m. by decapitation and the blood was collected in tubes for
serum leptin, glucose, total cholesterol and triglycerides mea-
surements. Blood samples were centrifuged at 1000 g for 20min
and the sera collected were kept at −70◦C until serum measure-
ments. Sera lipoprotein and triglycerides were determined by the
colorimetric method (Kit; Labtest, Minas Gerais, Brazil). Lep-
tin (R&D systems, Inc., Minneapolis, USA) concentrations were
determined by Elisa.
Oral Glucose Tolerance Test (OGTT)
Before this test, the diets were withdrawn for 6 h, and then
1.5g/kg body weight dose of dextrose was administered by gav-
age. Tail venous blood samples were collected immediately before
(0min) and at 30, 60, 120, and 180min after dextrose gavage. The
blood glucose level of these samples was analyzed using a glu-
cometer (Precision QID, Abbott Laboratories Medisense Prod-
ucts, Bedford, MA, USA). The data obtained were plotted, and
the area under the curve (AUC) was calculated.
Intravenous Insulin Tolerance Test (ivITT)
Rats were deprived of food for about 2 h and anesthetized with
ketamine plus xylazine (1:1, 0,1ml/kg), and then received an
intravenous injection of regular insulin (0.75U/kg body weight).
Glucose levels were measured on samples obtained from the
tail vein using a glucometer (Precision QID, Medisense, São
Paulo, SP, Brazil) immediately before (0min) and at 4, 8, 12, and
16min after insulin injection. The corresponding 4–16min val-
ues were used to calculate the rate constant for plasma glucose
disappearance (kITT).
Histological Analysis
Retroperitoneal adipose tissue of animal at 180 days of life
was fixed in 10% (v/v) formaldehyde/PBS and embedded in
paraffin, sliced (4µm) and staining with hematoxylin and
eosin. Morphometric parameters (number of cells per field
and major axis) were determined by computer-assisted image
analysis using software written in the macro language Quips
(Quantimet Interactive Programming System) of the Leica
Qwin package (Leica Microsystems Ltd., Cambridge, United
Kingdom).
Gene Expression Analyses
Total RNA from the WAT epididymal depot and hypothalamus
were extracted from control and enalapril treated animals at 180
days of life using the TRIzol R©Reagent (Invitrogen, USA) accord-
ing to the manufacture’s recommendation. One microgram of
RNA was reverse transcribed using Moloney Murine Leukemia
Virus reverse transcriptase (Invitrogen). First-strand cDNA syn-
thesized from total RNA with random hexamers was used as the
template for each reaction. The iCycler iQ Real Time PCR Detec-
tion System (Bio-Rad) was used for the signal detection, and the
PCR was performed using QuantiTec SYBR Green PCR (QUIA-
GEN GmbH, Germany) using 300 nmol/L of each primer. For
standardization and quantification, mice β-actin was amplified
simultaneously. The primer sequences employed for the ampli-
fication are shown in Table 1. PCR conditions were 50◦C for
2min, 95◦C for 10min, followed by 45 cycles at 95◦C for 15 s,
and 60◦C for 60 s. Fluorescence was detected at the end of every
extension phase (72◦C). Data generated from SYBR Green were
analyzed according (Livak and Schmittgen, 2001). Calculation of
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TABLE 1 | Primer sequences.
Transcript Gene symbol Forward Primer Reverse Primer
Neuropeptide Y NPY GAGGACGCGCCAGCAGAGG GTCTCAGGGCTGGATCTCTTGC
Cocaine- and amphetamine-regulated transcript CART GTGCCACGAGAAGGAGCTG CACATGGGGACTTGGCCGTAC
Proopiomelanocortin POMC TGCCAGGACCTCACCACGG GTGACCCATGACGTACTTCCGG
Agouti related protein AgRP GATGATCTGCTGCAGAAGGC TTGAAGAAGCGGCAGTAGCACG
Peroxisome proliferator-activated receptor alpha PPARα TCCACGAAGCCTACCTGAAG GAACTCTCGGGTGATGAAGC
Peroxisome proliferator-activated receptor gamma PPARγ AACATCCCCAACTTCAGCAG GGAAGAGGTACTGGCTGTCG
Uncoupling protein 2 UCP2 AATGTTGCCCGAAATGCC CAATGACGGTGGTGCAGAA
Uncoupling protein 3 UCP3 ATGGATGCCTACAGAACCAT CTGGGCCACCATCCTCAGCA
Fatty acid synthase FAS CTTGGGTGCCGATTACAACC GCCCTCCCGTACACTCACTC
Hormone-sensitive lipase HSL CCCATAAGACCCCATTGCCTG CTGCCTCAGACACACTCCTG
ß-actin ß-actin AGAGGGAAATCGTGCGTGAC CCATAGTGATGACCTGTCCGT
the fold change in specific gene each was relative to the β-actin
endogenous control using 2−1Ct.
Statistical Analysis
The data were subjected to unpaired t-test to compare animals
treated with saline (n = 20) and enalapril (n = 20). When
submitted to different diet [control (n = 10) or HFD (n =
10)] the animals were compared into the same treatment. Data
were expressed as means ± standard error of means (SEM).
Differences were considered significant at p < 0.05.
Results
Effects of Postnatal ACE Inhibition on Body Mass
Development
In order to evaluate the impact of postnatal ACE inhibition
on late body weight evolution, newborn rats were treated with
enalapril (10mg/kg) or saline for 16 days after birth. Body
weight was measured in the animals at birth and once a week
until the ninetieth day of life. It was observed on the six-
teenth day, end of the treatment, that the body weight was
similar between both groups of animals (25 ± 1 vs. 23 ±
1 g of BW, saline and enalapril), however on the ninetieth
day it was significantly higher in the enalapril treated group
(Figure 2A). Except for the inguinal WAT, all the other depots
increased in enalapril treated rats when compared to saline group
(Figure 2B).
Impact of HFD in the Body Weight of Rats
Treated with Enalapril
To analyze the sensitivity of the iACE treated animals to a hyper-
caloric regimen, as well as the evolution of the effects of enalapril
postnatal treatment, on the ninetieth day the rats were subdi-
vided in four groups and fed with control (CD) or high fat (HFD)
diet for 3 months. The rats treated with enalapril kept their over-
weight at the hundred and eightieth day (Figure 3A), showing an
elevated Lee index and food intake and hyperphagia (Table 2). In
addition, enalapril treated animals fed with HFD had the highest
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FIGURE 2 | (A) Body and (B) fat depot mass of 90 days old rats treated with
saline or enalapril (10 mg/Kg of BW) during the first 16 days after
birth.*p < 0.05, **p < 0.01 vs. saline treated animals. Data are shown as mean
+ SEM, n = 10 rats each group. Inguinal (iWAT), epididymal (eWAT),
retroperitoneal (rpWAT) and mesenteric (mWAT) fat depots mass.
increase in body weight at 180 days, showing a 24% overweight
when compared to control group (Figure 3A).
The transient treatment with iACE was able of modify the
body composition of the animals in adulthood. As shown in
Figures 3B,C, in the enalapril treated animals the fat mass was
increased in both diets whereas the lean mass was decreased. The
inguinal (iWAT), epididymal (eWAT), retroperitoneal (rpWAT),
and mesenteric (mWAT) fat depots mass, normalized by body
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FIGURE 3 | Effect of high fat diet in the mass and body composition
after postnatal enalapril treatment. (A) Body weight (BW), evolution of
adult rats treated with control (CD), and high fat (HFD) diet from the ninetieth
day until the hundred and eightieth day of life. (B) Percentage of fat, (C) lean
body mass, and (D) inguinal (i), epididimal (e), retroperitoneal (rp), and
mesenteric (m) fat depots of white adipose tissue (WAT) of rats treated with
saline (S) or enalapril (E) for 16 days after birth. *p < 0.05, **p < 0.01,
***p < 0.001 vs. control group (animals fed with the same diet). ##p < 0.01,
###p < 0.001 E-HFD vs. E-CD group. Data are shown as mean + SEM,
n = 10 rats each group.
TABLE 2 | Anthropometric data (body weight and Lee index), food intake, organs weight (kidney, liver and heart), and the index of water
consumption/urine excretion of rats treated with saline (S) or enalapril (E) and fed from day ninetieth to hundred and eightieth after birth with control (CD)
or high fat (HFD) diet.
Groups S-CD E-CD S-HFD E-HFD
Body Weight gain (g) 126± 5 179±12*** 158±5 235± 26**
Lee Index 6.3± 0.1 6.8±0.1** 6.5±0.2 7.2± 0.2*
Food intake (kJ/day) 284± 11 328±5** 305±4 338± 9**
Rate water/urine (g/g) 2.3± 0.5 1.6±0.1 1.8±0.6 2.0± 0.4
Kidney (% of BW) 0.18± 0.02 0.16±0.01 0.14±0.01 0.15± 0.01
Liver (% of BW) 2.8± 0.1 2.8±0.1 2.4±0.1 2.4± 0.1
Heart (% of BW) 0.17± 0.02 0.15±0.01 0.14±0.01 0.14± 0.01
Data are expressed as mean ± SEM of 10 animals/group. *p < 0.05, **p < 0.01, and ***p < 0.001 when compared S and E group in same diet. Lee index = rate body weight (g) and
by nasoanal lengths (mm).
weight, increased in enalapril treated animals in both diets in
180 days old rats, except eWAT in HFD (Figure 3D). On the
other hand, the iACE did not provoke any weight difference in
the heart, liver, and kidney (Table 2). No difference in rate of
water intake by urine excretion was observed between the groups
(Table 2).
Insulin Sensitivity and Glucose Tolerance
In order to evaluate the metabolic consequences of overweight
and elevated adiposity in the iACE treated rats, intravenous
insulin tolerance test (ivITT), and oral glucose tolerance test
(OGTT) were performed (AUC: 521 ± 18, 490 ± 16, 574 ±
28, 542 ± 13, S-CD, S-HFD, E-CD, E-HFD respectively;
p > 0.05 when groups in the same diet were compared).
Insulin and glucose tolerance were similar between the groups
(Figures 4A,B).
Lipid Profile, Glucose, and Leptin Levels of Rats
Treated with Enalapril
Accordingly to increased body weight and fat mass, enalapril
treated animals also showed elevated triglycerides, total
cholesterol and leptin level when compared to saline treated
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FIGURE 4 | Insulin sensitivity after postnatal enalapril treatment.
Animals treated with saline (S) or enalapril (E) during the first 16 days after birth
and fed from day ninetieth to hundred and eightieth after birth with control (CD)
or high fat diet (HFD) were submitted to (A) intravenous insulin test (0.75U/kg
body weight) and (B) oral glucose tolerance test (1.5 g of glucose/Kg of BW
by gavage). Data are shown as mean + SEM, n = 10 rats each group.
TABLE 3 | Lipid profile, glucose, and leptin levels in the serum of animals
treated with iACE (E–10mg/kg of BW) or saline (S) for 16 days after birth
and fed from day ninetieth to hundred and eightieth after birth with
control (CD) or high fat (HFD) diet.
Groups S-CD E-CD S-HFD E-HFD
Triglycerides (mg/dL) 156± 18 256±41* 95± 5 163±20**
Total cholesterol (mg/dL) 116± 12 154±10* 98± 2 131±6***
Glucose serum (mg/dL) 106± 3 111±10 108± 3 116±4
Leptin (ng/mL) 7± 1 11±2* 9± 1 17±4*
Data are expressed as mean ± SEM of 10 animals/group. *p< 0.05, **p< 0.01, and ***p
< 0.001 when compared to S and E group in same diet.
animals in the same diet (Table 3). No difference was observed
in serum glucose levels between the groups in both diets
(Table 3).
Histological Analysis of WAT in Adult Life
Histological analysis of the retroperitoneal WAT at 180 days
of life showed an increase in adipocyte size and a reduced
number of adipose cells in the enalapril treated animals fed
with both diets when compared to the respective control group
(Figures 5A–C).
Gene Expression in Rats after Postnatal Enalapril
Treatment
To elucidate the molecular basis of functional and histolog-
ical modifications observed in enalapril treated animals, we
investigated metabolism-related gene expression in rpWAT and
hypothalamus. In the rpWAT it was observed a reduced gene
expression of both PPARs (α and γ) and UCPs (2 and 3) isoforms
and elevation of FAS and HSLmRNA in enalapril treated animals
compared with control group (Figures 6A–F). Gene expression
analyses in hypothalamus reveal NPY and CARTmRNA increase
and proopiomelanocortin (POMC) mRNA decrease in enalapril
treated animals compared with control group (Figures 7A,C,D).
No difference was observed in agouti related protein (AgRP)
mRNA expression (Figure 7B).
Discussion
In this study, we showed that early postnatal treatment with
an ACE inhibitor, enalapril, applied to newborn rats during
the first 16 days after birth is responsible for a programming
in metabolism, favoring hyperphagia and WAT accumulation.
This altered metabolism results in overweight in adult life with
increased body adiposity, serum lipid profile, and leptin, despite
of preserved insulin sensitivity and serum glucose.
The reduced ACE activity with enalapril treatment affects at
least the function of two relevant physiological systems, RAS
and kallikrein-kinin system. Classically, these systems have been
linked to cardiovascular and inflammatory processes especially
in adult phase. However, both systems also have pivotal roles
during postnatal development and their activation can change
the maturation of the adipose tissue (Martins et al., 2008; Mori
et al., 2008). Obesity resistance phenotype has been generated
upon deletion of many receptors in these systems (Yvan-Charvet
et al., 2005; Mori et al., 2008) as well as of the AngII precursor
molecule angiotensinogen (Massiera et al., 2001), which corrob-
orates the physiological relevance of these systems in the regula-
tion of metabolic activity and body mass maintenance. Metabolic
alterations were also obtained with the insertion of three copies
of the ACE gene into the mouse genome, although divergent
data have been observed. In this case the genetic augmenta-
tion of ACE activity triggers a phenotype of decreased body
fat and mass under hyperlipidic diet (Heimann et al., 2005),
in opposition to other studies that point positive correlation
between ACE activity and obesity (Davidson et al., 2011). These
apparently contrasting findings could be due to other functions
attributed to ACE not related to AngII production, like the sig-
naling activity of the enzyme (Kohlstedt et al., 2005; Guimaraes
et al., 2011).
In the present study the activity of the RAS was inhibited only
during a specific postnatal phase and it was possible to verify that
the role of AngII in differentiation in adipose tissue (Ailhaud
et al., 2002) for the generation of adipogenic precursors can be
age-dependent. In our study, AngII blockade in early postnatal
life was able to modify adult WAT cellularity and metabolism.
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FIGURE 6 | Expression of lipolytic and lipogenic genes in the
retroperitoneal WAT after postnatal treatment with enalapril. Animals
were treated with saline (S) or enalapril (E–10mg/kg BW) during the first 16
days after birth and treated for 90 days with control diet. WAT was collected
and mRNA expression of (A) PPARγ, (B) PPARα, (C) UCP2, (D) UCP3, (E)
FAS, and (F) HSL was analyzed at 180 days of life. Data represent mean ±
SEM, n = 5 animals each group. *p < 0.05 and **p < 0.01 when compared
to the saline group.
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FIGURE 7 | Expression of hypothalamic genes after postnatal
treatment with enalapril. Animals were treated with saline (S) or
enalapril (E – 10mg/kg BW) during the first 16 days after birth and
treated for 90 days with control diet. Hypothalamus was collected
and mRNA expression of (A) NPY, (B) AgRP, (C) CART, and (D)
POMC was analyzed at 180 days of life. Data are present as
mean ± SEM, n = 5 animals each group. *p < 0.05 when compared
to the saline group.
Early postnatal enalapril treated rats show reduced hyperplasia
and elevated hypertrophy of retroperitoneal adipocytes. PPARγ
is highly expressed in adipose tissue, and is a transcription fac-
tor important to adipocyte differentiation and regulation of genes
involved in lipid utilization and storage (Powell et al., 2007;
Lee et al., 2011). PPAR agonists contribute to prevent obesity
in adult life and other associated diseases by decreasing adipos-
ity and increasing the expression of antioxidant and lipolytic
genes (Willson et al., 2001; Bassaganya-Riera et al., 2011). Many
in vitro studies (Albrektsen et al., 2002) indicate that PPARγ
activation agonists stimulate adipocyte differentiation through
the activation of a variety of adipogenic genes. PPARγ is essen-
tially required for the formation, differentiation, and survival of
WAT (Rosen et al., 1999; Imai et al., 2004). Enalapril treated rats
show decreased PPARα and PPARγ gene expression in retroperi-
toneal WAT, which is the key molecular mechanism to explain
the reduced number of adipose cells. The activation of PPARγ
causes structural remodeling of adipocytes in adult WAT that is
characterized by increased number of smaller adipocytes (Okuno
et al., 1998). The origin of these smaller adipocytes is postulated
to be the amplified differentiation of residential preadipocytes
or the active division of adipocytes themselves (Okuno et al.,
1998). Moreover, PPARα and PPARγ are nuclear regulators of
WAT, regulating UCP2 e UCP3 gene expression (Villarroya et al.,
2007).
UCP2 and UCP3 mRNA are positively correlated with PPARs
gene expression, which could express of body mass in enalapril
treated animals. UCP2 is expressed in many tissues and has been
considered a significant factor for basal metabolism (Gjedde et al.,
2010). Chronic treatment with rosiglitazone, a thiazolidinedione
capable of activating PPARγ, has been reported to involve an
induction in UCP3 mRNA levels in WAT (Matsuda et al., 1998;
Emilsson et al., 2000). Additionally, the revised data by Cecil
et al. (2006), about the role of PPARγ gene polymorphisms in the
energy balance and food intake, suggest that the role of PPARγ
is varied and complex, influencing the speed of fat deposition
and growth early in life, with potential impact in the control of
energy intake and appetite regulation. Gene expression of the
enzymes FAS and HSL are augmented in the enalapril treated
rats. These alterations contribute to the increase in triglycerides
and total cholesterol serum levels shown by the enalapril treated
rats.
Our data of transitory administration of enalapril in postna-
tal life are opposite to the findings of Basso et al. (2007) and
Santos et al. (2008) obtained by chronic enalapril treatment in
rats after weaning, which led to decreased body mass and lep-
tin serum level. The elevation in the body weight gain observed
in this work indicates a higher susceptibility to overweight in
the neonatal animals treated with ACE inhibitors, which could
reflect an AngII age-dependent effect on the metabolism during
development. Despite their common use as first-line therapy for
selected patients with chronic hypertension and for the preven-
tion of diabetic nephropathy, ACE inhibitors are not indicated
for women during pregnancy and lactation due to their excre-
tion into breast milk (Ghanem and Movahed, 2008). In addition
to their effects on the metabolism, Mecawi et al. (2009) have also
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FIGURE 8 | Enalapril administration in rats in postnatal life increases hypothalamic NPY gene expression, decreases expression of PPAR in the WAT
and leads to long term consequences in metabolism, WAT cellularity and obesity.
shown that ACE inhibition during prenatal and neonatal periods
affects behavioral responses in adult offspring rats, suggesting
that ACE is required for the development of neural systems
that are associated with adult anxiety and nociceptive behavioral
responses.
The increased food intake is in agreement with elevated
NPY gene expression and reduced POMC gene expression
in the enalapril treated rats. Together, an increased expres-
sion of an orexigen neuropeptide and a decreased expres-
sion of anorexigen neuropeptide trigger hyperphagia, and the
decreased metabolic profile of the WAT in enalapril treated
rats might be responsible for the overweight observed in ani-
mals. It is possible that leptin, although increased in enalapril
treated animals, might fail to reduce NPY expression as occurs
in obese humans due to resistance to its actions (Fried-
man, 2011). CART, an anorexigenic neuroptide, responsi-
ble for the elevation in energy expenditure in excess energy
state, can be induced by leptin levels elevation (Dominguez,
2006). Although enalapril treated rats have presented elevated
CART gene expression, this effect was not sufficient to coun-
terbalance the other modification in the opposite metabolic
direction.
Although the amount of leptin, fat mass, total cholesterol
and triglycerides were increased in enalapril treated rats, we
could not establish a correlation between insulin resistance and
higher body mass in this study. Other counter-regulators such as
adiponectin and TNFα, which had similar expression in saline
and enalapril treated rats (data not shown), have collaborated for
the maintenance of insulin sensitivity.
In conclusion, altogether our data show that postna-
tal early pharmacological inhibition of ACE modifies
the development of WAT and hypothalamus, leading to
hyperphagia, hyperlipidemia and overweight in adulthood
(Figure 8).
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